Legend Biotech Corporation is a global biopharmaceutical company. The Company is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
Símbolo de cotizaciónLEGN
Nombre de la empresaLegend Biotech Corp
Fecha de salida a bolsaJun 04, 2020
Director ejecutivoHuang (Ying)
Número de empleados2600
Tipo de seguridadDepository Receipt
Fin del año fiscalJun 04
Dirección2101 Cottontail Lane
CiudadSOMERSET
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal08873
Teléfono17328505598
Sitio Webhttps://investors.legendbiotech.com/
Símbolo de cotizaciónLEGN
Fecha de salida a bolsaJun 04, 2020
Director ejecutivoHuang (Ying)
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos